Tech Center 1600 • Art Units: 1641
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18362410 | IMMUNOMODULATORY PROTEINS AND RELATED METHODS | Non-Final OA | Flagship Pioneering Innovations VII, LLC |
| 18347362 | COMBINATION THERAPY EMPLOYING A PD1-LAG3 BISPECIFIC ANTIBODY AND A CD20 T CELL BISPECIFIC ANTIBODY | Non-Final OA | Hoffmann-La Roche Inc. |
| 18340608 | ANTI-HUMAN CYSTINOSIN ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18323914 | NON-VIRAL DELIVERY OF CELL THERAPY CONSTRUCTS | Final Rejection | Kite Pharma, Inc. |
| 18353183 | Synergistic Inhibition of eIF5A and Notch Signaling | Non-Final OA | The University of Toledo |
| 18271364 | Interleukin-37, Chimeric Antigen Receptors, Nucleic Acids, and Vectors Encoding the Same and Uses in Cancer Therapies | Non-Final OA | Children's Healthcare of Atlanta, Inc. |
| 18025204 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA | Non-Final OA | GENMAB A/S |
| 18452405 | EGFR TARGETING PEPTIDE CONJUGATE | Non-Final OA | Chapman University |
| 18262930 | BISPECIFIC CS1-BCMA CAR-T CELL AND APPLICATION THEREOF | Non-Final OA | WUHAN SIAN BIOTECHNOLOGY CO., LTD |
| 18256221 | MONOCLONAL ANTIBODY INHIBITING SMIM15 AND APPLICATION THEREOF | Non-Final OA | AFFILIATED HOSPITAL OF NANTONG UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy